• Publications
  • Influence
Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients
Tumor molecular profiling is a fundamental component of precision oncology, enabling the identification of genomic alterations in genes and pathways that can be targeted therapeutically. TheExpand
  • 950
  • 48
  • Open Access
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
A main limitation of therapies that selectively target kinase signalling pathways is the emergence of secondary drug resistance. Cetuximab, a monoclonal antibody that binds the extracellular domainExpand
  • 1,269
  • 42
  • Open Access
Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer.
Metastatic colorectal cancers (mCRCs) are clinically heterogeneous, but the genomic basis of this variability remains poorly understood. We performed prospective targeted sequencing of 1,134 CRCs. WeExpand
  • 155
  • 14
Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
PURPOSE Although neoadjuvant chemoradiotherapy achieves low local recurrence rates in clinical stages II to III rectal cancer, it delays administration of optimal chemotherapy. We evaluatedExpand
  • 276
  • 9
KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases
The validity of the KRAS mutation as a predictor of recurrence‐free survival (RFS) or overall survival (OS) is unclear. The current study investigated whether the presence of the KRAS mutationExpand
  • 88
  • 7
Comparative genomic analysis of primary versus metastatic colorectal carcinomas.
PURPOSE To compare the mutational and copy number profiles of primary and metastatic colorectal carcinomas (CRCs) using both unpaired and paired samples derived from primary and metastatic diseaseExpand
  • 219
  • 6
  • Open Access
Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels.
PURPOSE Tumor screening for Lynch syndrome is recommended in all or most patients with colorectal cancer (CRC). In metastatic CRC, sequencing of RAS/BRAF is necessary to guide clinical management. WeExpand
  • 125
  • 6
Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions
BackgroundColorectal cancer is the second leading cause of cancer death in the United States, with over 50,000 deaths estimated in 2014. Molecular profiling for somatic mutations that predict absenceExpand
  • 206
  • 5
Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions
In patients with colorectal cancer (CRC) that metastasizes to the liver, there are several key goals for improving outcomes including early detection, effective prognostic indicators of treatmentExpand
  • 77
  • 5
  • Open Access
Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients
Purpose: BRAF-mutant metastatic colorectal cancer (mCRC) forms an aggressive subset of colorectal cancer with minimal response to selective RAF inhibitors. Preclinical data show that reactivation ofExpand
  • 153
  • 4
  • Open Access